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Headaches and other cranio-oro-facial pains are widely
distributed in the general population. Unfortunately,
there is very little evidence regarding the impact of
these conditions in patients admitted to rehabilitation
units, regardless of the disease or syndrome requiring
rehabilitation. The availability of diagnostic and thera-
peutic guidelines, as well as the increasing number of
data coming from controlled clinical trials, should be
implemented in these patients to reduce the burden of
pain and improve their global outcome.
The Italian Society for Neurorehabiltation, in collabora-
tion with the Italian Society of Physical Medicine and Reha-
bilitation, has promoted the Consensus Conference on Pain
with the aim to foster attention on pain also in the rehabili-
tative field (http://www.doloreinneuroriabilitazione.it/).
The working group has proposed the following
recommendations:
- Standard methods or criteria exist to evaluate head
and cranio-facial pain in terms of intensity (B);
- Standard methods exist to evaluate migraine in
terms of disability (A);
- It is important to evaluate the impact of cephalic
and cranio-facial pain in neurorehabilitation (D);
- Standard methods or criteria exist to diagnose head
and cranio-facial pain (GL);
- It is important to identify predictive factors asso-
ciated with the development of cephalic and cranio-
facial pain in association with a condition requiring neu-
rorehabilitation (D);
- Effective pharmacological treatment exists for pri-
mary headaches and for trigeminal neuralgia (GL);
- Manual therapy is indicated in the management of
migraine and tension-type headache (GL);
- Manual therapy may be effective in TMD-associated
pain (D);
- Botulinum toxin A is effective in the treatment of
idiopathic trigeminal neuralgia (B);
- Botulinum toxin A is effective in the treatment of
hemifacial spasm (B);
- Topical capsaicin is effective in chronic neuropathic
pain (B);
- Evidence is needed to evaluate the impact of treating
cephalic and cranio-facial pain on the outcome of patients
undergoing neurorehabilitation (D).
The recommendations are presently under evaluation
by the Consensus Conference panel.
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